drugset / Trial / NCT00586105
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |